Saudi Arabia Warns Oil Prices Could Surge Past $180 a Barrel Amid U.S.-Israel-Iran Conflict 
U.S. Stock Futures Steady as Wall Street Retreats on Oil Volatility and Fed Rate Outlook 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
BOJ Holds Interest Rates Steady Amid Middle East Uncertainty 
Super Micro Computer Shares Plunge After Co-Founder Charged in AI Chip Smuggling Case 
Asian Markets Mixed as Oil Volatility and Inflation Fears Weigh on Sentiment 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Xiaomi's AI Model "Hunter Alpha" Mistaken for DeepSeek's Next Release 
Elliott Investment Management Takes Activist Stake in Align Technology 
Microsoft Eyes Legal Action as Amazon-OpenAI Deal Threatens Azure Exclusivity 
Paraguay Central Bank Holds Interest Rate at 5.5% Amid Slowing Growth 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes 
U.S.-Iran War Escalates: Marines Deploy, Strait of Hormuz Closure Drives Global Oil Crisis 
Iran War Fears Send Oil Prices Surging as U.S. Weighs Ground Troop Deployment 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis 
Lotte Group is set to acquire a bioindustry CMO plant located in the United States. The move has been announced on Thursday, May 5, and this also signals the company’s entrance into the bio business.
Currently, the acquisition process for the contract manufacturing organization (CMO) facility is still ongoing. Investment banking industry insiders said that Lotte Group has taken this step to buy the CMO plant after it stated that the bioindustry will be its new growth engine.
According to The Korea Times, CMOs are firms that specialize in the production of biopharmaceuticals that were developed by other companies. Lotte Group’s new CMO business will be headed by Lee Won Jik, a former executive at Samsung Biologics that the company recently hired. He has been tasked to develop and grow this business unit that the Lotte Group set up.
Lee will also be leading the acquisition efforts of the CMO as per the report. It was only last month when the South Korean multinational conglomerate declared during its general shareholders' meeting that its next growth engine for the future will be the bioindustry. Lotte Holdings will be investing directly in this business and will provide support to help it grow and succeed.
Meanwhile, as part of its entrance into the CMO business, Lotte Group applied for a trademark for its new biz. The company registered “Lotte Biologics” with the Korean Intellectual Property Office (KIPO) to officially launch its bio venture.
It was added that under the new Lotte Biologics banner, Lotte will also be participating in the largest bioindustry expo in the world called the Bio International Convention (Bio USA) which is set to take place next month in San Diego, California.
KIPO revealed that Lotte Holdings applied for the patent last week and aside from the name, it also trademarked some business areas such as customized manufacturing of biopharmaceuticals and drug processing and medical diagnostic devices for virus testing, The Korea Herald reported.
“Registering the trademark of Lotte Biologics was a part of preparations for the group’s bio business,” an official of Lotte Holdings stated. “We are reviewing various ways to enter the bio industry, but nothing has been confirmed at the moment.”
